Medisearch Clinical Trials

Futó vizsgálatok

• Fut, nem toboroz

  A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

  NCT07265479· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

  NCT06832618· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

  NCT06095102· 3. fázis· Forrás

• Fut, nem toboroz

  Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

  NCT04674683· 3. fázis· Forrás

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

  NCT07150845· 2. fázis· Forrás

• Lezárult

  A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  NCT06921759· 3. fázis· Forrás

• Lezárult

  A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

  NCT05638802· 1/2. fázis· Forrás

• Lezárult

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· 3. fázis· Forrás

• Lezárult

  A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

  NCT05369403· 3. fázis· Forrás

• Leállították

  An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

  NCT05399368· 2. fázis· Forrás

• Lezárult

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· 3. fázis· Forrás

• Lezárult

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· 3. fázis· Forrás